TBG Diagnostics (OTCMKTS:TDLAF) & TerrAscend (OTCMKTS:TRSSF) Head to Head Review

Insider and Institutional Ownership

0.0% of TerrAscend shares are owned by institutional investors. 32.9% of TerrAscend shares are owned by insiders. Comparatively, 3.6% of TBG Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares TerrAscend and TBG Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TerrAscend	-125.03%	-6.66%	-3.07%
TBG Diagnostics	N/A	N/A	N/A

Risk and Volatility

TerrAscend has a beta of 2.89, suggesting that its stock price is 189% more volatile than the S&P 500. Comparatively, TBG Diagnostics has a beta of -12.38, suggesting that its stock price is 1,338% less volatile than the S&P 500.

Earnings & Valuation

This table compares TerrAscend and TBG Diagnostics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TerrAscend	$247.83 million	0.58	-$329.91 million	($0.14)	-4.11
TBG Diagnostics	$2.33 million	1.02	$530,000.00	N/A	N/A

TBG Diagnostics has lower revenue, but higher earnings than TerrAscend.

Summary

TBG Diagnostics beats TerrAscend on 5 of the 9 factors compared between the two stocks.

About TerrAscend

TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. The company produces and distributes hemp-derived wellness products to retail locations; and manufactures cannabis-infused artisan edibles. It also operates retail dispensaries under the Apothecarium brand name in California, Pennsylvania, and New Jersey. In addition, the company owns various synergistic businesses under Gage Growth, Pinnacle, TerrAscend NJ, Ilera Healthcare, HMS Health and HMS Processing, Valhalla Confections, State Flower, Arise Bioscience Inc., and TerrAscend Canada brands. It serves medical and legal adult-use markets. The company was incorporated in 2017 and is headquartered in Mississauga, Canada.

About TBG Diagnostics

TBG Diagnostics Limited, a molecular diagnostics company, develops, manufactures, and markets molecular diagnostics kits, instruments, and services in Taiwan and China. It provides ExProbe HLA and HPA kits for human leukocyte antigen (HLA) and human platelet antigens (HPA) allele genotyping, which uses real time polymerase chain reaction (PCR) techniques with sequence specific primers and probes; Morgan SSP HLA kits for determining HLA alleles using PCR techniques with sequence specific primers; HLAssure SBT HLA Kits for transplantation donor selection; and AccuType SBT analysis software to analyze sequences from all ab1 based files. The company also offers Morgan SSPal HLA Typing Analysis Software, a gel result interpretation software; HLA typing services that offer low to high resolution using PCR fragment analysis (SSP) and DNA sequencing (SBT); QPCR Q6000, a six-channel real time PCR instrument; QzNGS NGS that provides high resolution HLA genotyping; and COVID-19 testing kits. It serves clinical labs, blood centers, and bone marrow registry labs. The company was formerly known as Progen Pharmaceuticals Limited and changed its name to TBG Diagnostics Limited in December 2015. TBG Diagnostics Limited was incorporated in 1989 is based in Greenslopes, Australia.